Study Summary
This is a open-label to assess the efficacy and safety of IM19 CAR-T cells in R/R B-cell Acute Lymphoblastic Leukemia.
Want to learn more about this trial?
Request More InfoInterventions
IM19 CAR-T cellsBIOLOGICAL
IM19 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| First Hospital of China Medical University | Shenyang | Liaoning | China |